Europe - Euronext Milan - BIT:1BSX - US1011371077 - Common Stock
The current stock price of 1BSX.MI is 81.4 EUR. In the past month the price decreased by -3.1%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 17.78 | 109.86B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 19.47 | 52.49B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 16.89 | 24.07B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 17.09 | 24.35B | ||
| BIM.PA | BIOMERIEUX | 29.46 | 13.46B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 151.76 | 4.56B | ||
| DIA.MI | DIASORIN SPA | 21.93 | 4.06B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 26.04 | 3.75B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 11.46 | 1.39B | ||
| ELN.MI | EL.EN. SPA | 22.53 | 1.16B | ||
| DRW8.DE | DRAEGERWERK AG | 9.27 | 1.12B | ||
| EUZ.DE | ECKERT & ZIEGLER SE | 23.87 | 985.51M |
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS US
Employees: 53000
Phone: 15086834000
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
The current stock price of 1BSX.MI is 81.4 EUR.
1BSX.MI does not pay a dividend.
1BSX.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
40 analysts have analysed 1BSX.MI and the average price target is 108.56 EUR. This implies a price increase of 33.36% is expected in the next year compared to the current price of 81.4.
BOSTON SCIENTIFIC CORP (1BSX.MI) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1BSX.MI.
ChartMill assigns a technical rating of 3 / 10 to 1BSX.MI.
ChartMill assigns a fundamental rating of 5 / 10 to 1BSX.MI. Both the profitability and the financial health of 1BSX.MI get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months 1BSX.MI reported a non-GAAP Earnings per Share(EPS) of 2.52. The EPS increased by 25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.42% | ||
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| Debt/Equity | 0.48 |
40 analysts have analysed 1BSX.MI and the average price target is 108.56 EUR. This implies a price increase of 33.36% is expected in the next year compared to the current price of 81.4.
For the next year, analysts expect an EPS growth of 22.13% and a revenue growth 20.9% for 1BSX.MI